Additionally, previous studies have suggested knockdown of SMARCE1 sensitizes ovarian cancer to chemotherapy treatment, and thus testing a combination treatment with carboplatin or paclitaxel, the current regimen of ovarian cancer chemotherapy treatment, may optimize tumor regression (50). The gene discussed is SMARCE1; the disease is ovarian carcinoma.